https://doi.org/10.1186/s12967-018-1663-8
E
Emi Tokuda
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
69
Papers
818
Citations
17
h-index
20
i10-index
Emi Tokuda is an academic researcher from Fukushima Medical University. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology. The author has an h-index of 17, co-authored 59 publications.
ORCID: 0000-0001-6274-1144Papers by this author
worksAnalysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study
2018 · Journal of Translational Medicine · 69 citations
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
2023 · Breast Cancer · 53 citations
https://doi.org/10.1007/s12282-023-01505-x
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases
2014 · British Journal of Cancer · 44 citations
https://doi.org/10.1038/bjc.2014.595
Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
2014 · BMC Cancer · 27 citations
https://doi.org/10.1186/1471-2407-14-550
Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
2018 · Medical Oncology · 8 citations
https://doi.org/10.1007/s12032-018-1112-9
Is adjuvant chemotherapy necessary in older patients with breast cancer?
2022 · Breast Cancer · 8 citations
https://doi.org/10.1007/s12282-021-01329-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat